Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...

Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released clinical trial results for its oral ...

Key Takeways U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly shares are now positive for the year, up 10% since the start of January.

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

We recently published a list of 15 Best Blue Chip Stocks to Buy According to Billionaires. In this article, we are going to ...

Shares in pharmaceuticals firm Eli Lilly (LLY) ballooned higher today after revealing its new needle-free weight loss drug had performed ...